Source: BEFREE

Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5294
Gene Symbol: PIK3CG
PIK3CG
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease 		0.060 Biomarker BEFREE Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. 24251790

2013
Entrez Id: 5294
Gene Symbol: PIK3CG
PIK3CG
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease 		0.060 GeneticVariation BEFREE Hemopoietic progenitor cells (HPC) from myeloproliferative neoplasms (MPN) such as myelofibrosis commonly express mutant JAK2-V617F or other mutations that are associated with increased activities of JAK-STAT5/3, RAS/RAF/MAPK, and PI3K/AKT/mTOR pathways. 23445613

2013
Entrez Id: 5294
Gene Symbol: PIK3CG
PIK3CG
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease 		0.060 AlteredExpression BEFREE Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. 24237791

2013
Entrez Id: 5294
Gene Symbol: PIK3CG
PIK3CG
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease 		0.060 Biomarker BEFREE Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. 24290217

2013
Entrez Id: 5294
Gene Symbol: PIK3CG
PIK3CG
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease 		0.060 GeneticVariation BEFREE The majority of patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN) harbor mutations in JAK2 or MPL, which lead to constitutive activation of the JAK/STAT, PI3K and ERK signaling pathways. 23748344

2013
Entrez Id: 5294
Gene Symbol: PIK3CG
PIK3CG
CUI: C0027022
Disease: Myeloproliferative disease
Myeloproliferative disease 		0.060 Biomarker BEFREE In summary we describe a pathway involving PI3K/Rho/ROCK/MLC that may contribute to myeloproliferative disease and/or acute myeloid leukemia in humans. 21907926

2011